Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

NCT06262581 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

DMMR Colorectal Cancer
Anti PD-1
Immunotherapy

Interventions

DRUG: Tisleizumab(BGB-A317)

Sponsor

Sun Yat-sen University